SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres

Investigational New Drugs

Volumn 32, Issue 3, 2014, Pages 412-423

  Benbrook, Doris Mangiaracina ^a   Nammalwar, Baskar ^b   Long, Andrew ^a   Matsumoto, Hiroyuki ^a   Singh, Anil ^a   Bunce, Richard A ^b   Berlin, K Darrell ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Heteroarotinoids; HSPA9; Mortalin; Ovarian cancer; p53; p66shc

Indexed keywords

ANTINEOPLASTIC AGENT; AROTINOID; DEXTRAN SULFATE; HEAT SHOCK PROTEIN; MICROSPHERE; MORTALIN; P66 SRC HOMOLOGOUS COLLAGEN HOMOLOGUE; PROTEIN P53; PROTEIN SH2; SULFUR HETEROAROTINOID A2; UNCLASSIFIED DRUG; (((4-NITROPHENYL)AMINO)(2,2,4,4-TETRAMETHYL THIOCHROMAN-6-YL)AMINO) METHANE-1-THIONE; CHROMAN DERIVATIVE; HEAT SHOCK PROTEIN 70; PROTEIN SHC; SHC1 PROTEIN, HUMAN; THIOKETONE;

AFFINITY CHROMATOGRAPHY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; MASS SPECTROMETER; MASS SPECTROMETRY; METABOLITE; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; MAGNETISM; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMANS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MAGNETIC PHENOMENA; MICROSPHERES; SHC SIGNALING ADAPTOR PROTEINS; THIONES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904670850     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0041-x     Document Type: Article

References (46)

1. Zhang Y, Hua Y, Benbrook DM, Covey JM, Dai G, Liu Z, Chan KK (2006) High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother Pharmacol 58:561-569. doi:10.1007/s00280-006-0211-z (Pubitemid 44167380)
2. Liu Z, Zhang Y, Hua YF, Covey JM, Benbrook DM, Chan KK (2008) Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry. Rap Comm Mass Spec 22:3371-3381. doi:10.1002/rcm.3744
3. Mic FA, Molotkov A, Benbrook DM, Duester G (2003) Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. PNAS USA 100:7135-7140. doi:10.1073/pnas.1231422100 (Pubitemid 36706405)
4. Doppalapudi RS, Riccio ES, Davis Z, Menda S, Wang A, Du N, Green C, Kopelovich L, Rao CV, Benbrook DM, Kapetanovic IM (2012) Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. Mutat Res 746:78-88. doi:10.1016/j.mrgentox.2012.03.009
5. Kabirov KK, Kapetanovic IM, Benbrook DM, Dinger N, Mankovskaya I, Zakharov A, Detrisac C, Pereira M, Martín-Jiménez T, Onua E, Banerjee A, van Breemen RB, Nikolić D, Chen L, Lyubimov AV (2012) Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. Drug Chem Toxicol 36:284-295. doi:10.3109/01480545.2012.710632
6. Benbrook DM, Kamelle S, Guruswamy S, Lightfoot S, Rutledge T, Gould N, Hannafon B, Dunn ST, Berlin KD (2005) Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Inv New Drugs 23:417-428. doi:10.1007/s10637-005-2901-5 (Pubitemid 41166547)
7. Liu T, Masamha CP, Chengedza S, Berlin KD, Lightfoot S, He F, Benbrook DM (2009) Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther 8(5):1227-1238. doi:10.1158/1535-7163.MCT-08-1069
8. Naylor M, Thompson DM, Lightfoot S, Benbrook DM (2013) Anticancer activities and interaction of imiquimod and Flex-Het, SHetA2, in melanoma and ovarian cancer. J Cancer Ther 4:7-19. doi:10.4236/jct.2013.46A1002
9. Benbrook DM, Guruswamy S, Wang Y, Sun Z, Mohammed A, Zhang Y, Li Q, Rao CV (2013) Chemoprevention of colon and small intestinal tumorigenesis in APCmin/+ Mice By SHetA2 (NSC721689) without toxicity. Cancer Prev Res 6:908-916. doi: 10.1158/1940-6207.capr-13-0171
10. Moxley KC, Chengedza S, Benbrook DM (2009) Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: the search for sensitizing agents. Gyn Onc 115:438-442. doi:10.1016/j.ygyno.2009.09.007
11. Chengedza S, Benbrook DM (2010) NF-kB is involved in SHetA2 circumvention of TNF-a resistance, but not induction of intrinsic apoptosis. Anti-Cancer Drugs 21:297-305. doi:10.1097/CAD.0b013e3283350e43
12. Masamha CP, Benbrook DM (2009) Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 69:6565-6572. doi:10.1158/0008-5472.CAN-09-0913
13. Liu T-Z, Hannafon B, Gill L, Kelly B, Benbrook DM (2007) Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol Cancer Ther 6:1814-1822. doi: 10.1158/1535-7163.MCT- 06-0279 (Pubitemid 46954058)
14. Long A, Masamha CP, Zhao D, Benbrook DM (2013) Differential roles of autophagy in ovarian cancer and healthy cells in response to SHetA2 Drug. Cell Death Dis:publication pending review of revision
15. Chun K-H, Benbrook DM, Berlin KD, Hong WK, Lotan R (2003) Induction of apoptosis in head and neck squamous cell carcinoma (HNSCC) cell lines by heteroarotinoids through a mitochondrial dependent pathway. Cancer Res 63:3826-3832, http://cancerres.aacrjournals.org/content/63/13/3826.abstract
16. Liu S, Brown CW, Berlin KD, Dhar A, Guruswamy S, Brown D, Gardner GJ, Birrer MJ, Benbrook DM (2004) Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem 47:999-1007. doi:10.1021/jm030346v (Pubitemid 38176803)
17. Benbrook DM, Madler MM, Spruce LW, Birckbichler PJ, Nelson EC, Subramanian S, Weerasekare GM, Gale JB, Patterson MK Jr, Wang B, Wang W, Lu S, Rowland TC, DiSilvestro P, Lindamood C III, Hill DL, Berlin KD (1997) Biologically active heteroarotinoids exhibit anticancer activity and decreased toxicity. J Med Chem 40: 3567-3583 (Pubitemid 27465089)
18. Guruswamy S, Lightfoot S, Gold M, Hassan R, Berlin KD, Ivey RT, Benbrook DM (2001) Effects of retinoids on cancerous phenotype and apoptosis in organotypic culture of ovarian carcinoma. J Nat Cancer Inst 93:516-525. doi:10.1093/jnci/93.7.516 (Pubitemid 32318430)
19. Ziegler S, Pries V, Hedberg C, Waldmann H (2013) Target identification for small bioactive molecules: finding the needle in the haystack. Angew Chemie Int Ed 52:2744-2792. doi:10.1002/anie.201208749
20. Lomenick B, Olsen RW, Huang J (2010) Identification of direct protein targets of small molecules. ACS Chem Biol 6(1):34-46. doi:10.1021/cb100294v
21. Nammalwar B, Bunce RA, Benbrook DM, Lu T, Li H-F, Chen Y-D, Berlin KD (2011) Synthesis of N-[3,4-dihydro-4-(acetoxymethyl)-2, 2,4-trimethyl-2H-1- benzothiopyran-6-yl]-N′-(4-nitrophenyl)thiourea and N-[3,4-dihydro-4- (hydroxymethyl)-2,2,4-trimethyl-2H-1-benzothiopyran-6-yl]-N′-(4- nitrophenyl)thiourea, a major metabolite of N-(3,4-Dihydro-2,2,4,4-tetramethyl- 2H-1-benzothiopyran-6-yl)-N′-(4-nitrophenyl)thiourea. Phosphorus Sulfur Silicon Rel Elem 186:189-204. doi:10.1080/10426507.2010.534521
22. Keller A, Nesvizhskii AI, Kolker E, Aebersold R (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74:5383-5392. doi:10.1021/ac025747h (Pubitemid 35215372)
23. Nesvizhskii AI, Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75:4646-4658. doi:10.1021/ac0341261 (Pubitemid 37082259)
24. Londono C, Osorio C, Gama V, Alzate O (2012) Mortalin, apoptosis, and neurodegeneration. Biomol 2:143-164. doi:10.3390/biom2010143
25. Benbrook DM (2002) Refining retinoids with heteroatoms. Minirev Med Chem 2:271-277. doi:10.2174/1389557023406160
26. Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, Khuri FR, Sun S-Y (2008) Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther 7:3556-3565. doi:10.1158/1535-7163.MCT-08- 0648
27. Deocaris CC, Kaul SC, Wadhwa R (2006) On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60. Cell Stress Chap 11:116-128. doi:10.1379/CSC-144R.1
28. Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D, Martin-Padura I, Pelliccia G, Trinei M, Bono M, Puri C, Tacchetti C, Ferrini M, Mannucci R, Nicoletti I, Lanfrancone L, Giorgio M, Pelicci PG (2004) The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential. J Biol Chem 279: 25689-25695. doi:10.1074/jbc.M401844200 (Pubitemid 38756832)
29. Xu L, Voloboueva LA, Ouyang Y, Emery JF, Giffard RG (2008) Overexpression of mitochondrial Hsp70/Hsp75 in rat brain protects mitochondria, reduces oxidative stress, and protects from focal ischemia. J Cereb Blood Flow Metab 29:365-374
30. Lin Y-D, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun S-Y (2008) CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res 68(13):5335-5344. doi:10.1038/jcbfm.2008.125
31. Gestl EE, Anne Bottger S (2012) Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines. Biochem Biophys Res Comm 423:411-416. doi:10.1016/j.bbrc.2012.05.139
32. Grover A, Priyandoko D, Gao R, Shandilya A, Widodo N, Bisaria VS, Kaul SC, Wadhwa R, Sundar D (2012) Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence. Int J Biochem Cell Biol 44:496-504. doi: 10.1016/j.biocel.2011.11.021
33. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R, Luk JM (2011) Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. Int J Cancer 129:1806-1814. doi:10.1002/ijc.25857
34. Liu T, Laurell C, Selivanova G, Lundeberg J, Nilsson P, Wiman K (2007) Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis. Cell Death Differ 14:411-421. doi:10. 1038/sj.cdd.4402022
35. Su Z, Lebedeva I, Sarka RD, Gopalkrishnan R, Sauane M, Sigmon C, Yacoub A, Valerie K, Dent P, Fisher P (2003) Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 22:1164-1180. doi:10.1038/sj.onc.1206062 (Pubitemid 36363380)
36. Skolnik E, Lee C, Batzer A, Vicentini L, Zhou M, Daly R, Myers M, Backer J, Ullrich A, White M (1993) The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 12:1929-1936, http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC413414/ (Pubitemid 23157709)
37. VanderKuur J, Allevato G, Billestrup N, Norstedt G, Carter-Su C (1995) Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2. J Biol Chem 270:7587-7593. doi:10.1074/jbc.270.13.7587
38. Smit L, de Vries-Smits A, Bos J, Borst J (1994) B cell antigen receptor stimulation induces formation of a Shc-Grb2 complex containing multiple tyrosine-phosphorylated proteins. J Biol Chem 269:20209-20212, http://www.jbc.org/content/269/32/20209.long (Pubitemid 24260410)
39. Nemoto S, Finkel T (2002) Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295:2450-2452. doi:10.1126/science. 1069004 (Pubitemid 34270258)
40. Hu Y, Wang X, Zeng L, Cai D, Sabapathy K, Goff S, Firpo E, Li B (2005) ERK phosphorylates p66shcA on Ser36 and subsequently regulates p27kip1 expression via the Akt-FOXO3a pathway: implication of p27kip1 in cell response to oxidative stress. Mol Biol Cell 16:3705-3718. doi:10.1091/mbc.E05-04-0301 (Pubitemid 41077080)
41. Timofeeva O, Tarasova N, Zhang X, Chasovskikh S, Cheema A, Wang H, Brown M, Dritschilo A (2013) STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. PNAS USA 110:1267-1272. doi:10.1073/pnas.1211805110
42. Greer E, Oskoui P, Banko M, Maniar J, Gygi M, Gygi S, Brunet A (2007) The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 282:30107-30119. doi:10.1074/jbc. M705325200 (Pubitemid 350035296)
43. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RTP, Wadhwa R, Luk JM (2011) Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ 18(6):1046-1056. doi:10.1038/cdd.2010.177
44. Yang L, Liu X, Hao J, Yang Y, Zhao M, Zuo J, Liu W (2008) Glucose-regulated protein 75 suppresses apoptosis induced by glucose deprivation in PC12 cells through inhibition of Bax conformational change. Acta Biochimet Biophys Sin 40:339-348. doi:10.1111/j.1745-7270.2008.00409.x (Pubitemid 351572115)
45. Qu M, Zhou Z, Chen C, Li M, Pei L, Yang J, Wang Y, Li L, Liu C, Zhang G, Yu Z, Wang D (2012) Inhibition of mitochondrial permeability transition pore opening is involved in the protective effects of mortalin overexpression against beta-amyloid-induced apoptosis in SH-SY5Y cells. Neurosci Res 72:94-102. doi:10.1016/j.neures.2011.09.009
46. Yang L, Guo W, Zhang Q, Li H, Liu X, Yang Y, Zuo J, Liu W (2011) Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions. J Mol Biol 414:654-666. doi: 10.1016/j.jmb.2011.09.009